American Oriental Bioengineering announced another solid financial performance in Q3. The company’s revenues rose 62% to $70.6 million, and net income was higher by 38% at $16.5 million or 21 cents per diluted share. According to the company, net income failed to keep pace with the rise in revenues because of higher sales and marketing expenditures and because of amortization of costs from acquisitions. More details...

Stock Symbol: (NYSE: AOB)